Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Merck Sharp & Dohme LLC | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to better estimate the prevalence of urinary tract infections (UTI) in kidney transplant (KIT) recipients, and especially multidrug resistant (MDR) bacteria. KIT recipients have a higher risk of UTI over the 6 first months following the transplantation. Urine culture was done in a city lab or at hospital. Current data on bacteriuria and candiduria lead mostly to hospital data that are incomplete..
The risk of UTI after a kidney transplantation is higher than in the general population. MDR bacteria, such as extended spectrum betalactamase (ESBL)-producing enterobacteriaceae or MDR Pseumomoas aeruginosa are emerging threats due to antibiotic selective pressure. Epidemiological data are mostly data from hospital laboratories that do not show a complete overview of the current situation. In addition, the different centers which participated to this study received before the beginning of the study a protocol to avoid carbapenem use. The main objective of this study is to assess the prevalence of MDR bacteria in an adult population of KIT recipients. Through this study, the management of UTI in KIT recipients will be improved. Data on bacteria or yeasts responsible for UTI (identification, resistance profile), antibiotic use, patients' outcome, and graft outcome will be collected.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | No intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of UTI due to MDR bacteria | Proportion of MDR bacteria compared to other bacteria found in urinalysis of symptomatic KIT patients | Day 0 to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Epidemiology of UTI in KIT recipients | Frequency of each bacteria or yeasts responsible for UTI | Day 0 to 2 years |
| Risk factors for MDR UTI | Comparison of demographic and clinical characteristic of patients who develop an MDR versus a non-MDR UTI |
Not provided
Inclusion criteria
Exclusion criteria
Not provided
Not provided
Not provided
Male and female
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Isabelle PIRONNEAU | Contact | 0549443203 | isabelle.pironneau@chu-poitiers.fr | |
| François ARRIVE | Contact | 0630791699 | francois.arrive@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Antoine THIERRY, PHD | Poitiers University Hospital | Principal Investigator |
| Blandine RAMMAERT | Poitiers University Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Poitiers | Recruiting | Poitiers | 86000 | France |
No plan will be sharing with others researchers
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014552 | Urinary Tract Infections |
| ID | Term |
|---|---|
| D007239 | Infections |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 0 to 2 years |
| Carbapenem use to treat UTI | Proportion of patients who received carbapenem for UTI treatment | Day 0 to 2 years |
| Coherence between antibiotic protocol and treatment received to treat UTI | Proportion of patients who received carbapenem while responsible bacteria was susceptible to other antibiotics | Day 0 to 2 years |
| UTI relapse frequency | Proportion of patients with at least one relaspe of UTI with the same bacteria | Day 0 to 2 years |
| UTI recurrence frequency with a different micororganism | Proportion of patients with more than one UTI during the study period | Day 0 to 2 years |
| Assessment of kidney function during the observation period | Difference between the initial kidney function (MDRD) and the final kidney function at the end of the observation period | Day 0 to 2 years |
| Graft outcome | Number of patients needed a dialysis | Day 0 to 2 years |
| Patients outcome | Number of deaths | Day 0 to 2 years |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |